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Abstract 
 
Introduction 
Antipsychotics are used for the treatment of psychotic disorders, most commonly schizophrenia, as 
well as mood disorders e.g. bipolar mood d isorder. The efficacy of the newer second generation 
(atypical) antipsychotics is equivalent to first generation antipsychotics. The apparent advantage of the 
second generation antipsychotics is related to their purported reduced side effect profile, thus making 
them more desirable due to improved compliance and relapse prevention. The limiting factor with this 
class of drugs, especially in the state sector in South Africa, has been the cost. However, reports of 
treatment-emergent adverse events such as diabetes mellitus, diabetic ketoacidosis, hyperglycaemia 
and dyslipidaemia in patients receiving second generation antipsychotics have increased in recent 
times. This has lead to growing concern about the link between metabolic complications and their use, 
with consequent reconsideration of the implications of prescribing. 
 
Aims 
The study aimed to establish the extent to which metabolic and cardiovascular screening and 
monitoring has been undertaken on patients who have been prescribed olanzapine, a second generation 
antipsychotic. Specifically the extent to which the American Diabetes Association Consensus 
Conference monitoring protocols were being implemented in a specialist psychiatric South African 
setting i.e.: at Tara: The H. Moross Centre’s outpatient department. 
 
Objectives 
The study objectives were to describe the demographic profile, clinical diagnosis and risk factors for 
metabolic complications in a sample of patients receiving olanzapine. Further, to establish the extent to 
which metabolic and cardiovascular screening and monitoring has been undertaken on patients 
prescribed olanzapine as well as to what extent the patients’s demographics, diagnosis and metabolic 
risk factors influenced the treating doctor’s adherence to screening guidelines.    
 
Method 
This study was undertaken at Tara: The H. Moross Centre (outpatient department). A convenience 
sample of patients prescribed olanzapine were selected as the study group. The study involved a review 
of case records. It was a retrospective descriptive study. Relevant data was entered on a data sheet, 
designed for the study in accordance with the objectives and adapted from the American Diabetes 
Association Consensus Development Conference on Antipsychotic Drugs, Obesity and Diabetes. The 
data sheet is based on an existing protocol for monitoring metabolic status.  
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Frequencies for the presence or absence of evidence of screening or monitoring for metabolic 
complications were established, as per American Diabetes Association monitoring protocol 
requirements. Although the study involved outpatients, not all patients were intiated on olanzapine as 
outpatients i.e. some of the prescribing was inpatient initiated. 
  
Results 
The sample comprised of 19 females and 20 males. 48.72% female and 51.28% male.  The mean age of 
females in the sample was 52.38 years (SD=16.20) and the mean age of males was 41.28 (SD=17.05) 
years. The sample were predominantly single ( 61.54% n=24 ) with the majority being white (79.49% 
n=31 ); most had either tertiarty (43% n=17 ) or secondary (53.85% n =21 ) level of education. Only 
2.56% (n=1) had only primary level education. With regards to the diagnoses of patients in the sample, 
17,95%  (n=7) were diagnosed with bipolar 1 disorder, 7.69% (n=3) with major depressive disorder 
with psychosis, 20,51% (n=8) schizoaffective disorder and 53,84% (n=21) with schizophrenia. The 
percentage of screening for all the parameters was generally less than 20% and it continued to decline 
to less than 20% until 4 months. The exception was weight, where frequency increased slightly over 
time.  Comparing inpatient vesus outpatient initiated treatment there were apparent differences in the 
extent of screening i.e. greater for inpatient initiated treatment, specifically with respect to weight and 
blood pressure.   
 
Conclusion 
The current study was conducted in a very specific setting, but the findings demonstrated an area 
requiring attention i.e. adherence to acceptable clinical guidelines. Whilst one can only speculate on the 
basis for non-adherence, having established the status quo, there is a requirement for an appropriate 
strategy to address the deficit, given the implications of inadequate monitoring.  
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Literature Review 
Introduction 
Antipsychotics are used for the treatment of psychotic disorders, most commonly schizophrenia, as 
well as mood disorders such as bipolar mood disorder. Second generation antipsychotics (SGAs) e.g. 
risperidone and olanzapine are newer drugs whose development has followed that of their 
predecessors, the typical or first generation antipsychotics e.g. haloperidol, trifluoperazine. The main 
difference between these 2 classes is that second generation antipsychotics have prominent antagonism 
at the serotonin 2A receptor as well as dopamine D2 receptor blockade. Thus, these are serotonin-
dopamine antagonists. The ratio of serotonin to dopamine blockade is generally higher for these agents 
and they appear to be more selective for the mesolimbic dopamine pathway, which is thought to be 
important in mediating antipsychotic action. SGAs have relatively less action on the nigrostriatal 
pathway thereby minimising extrapyramidal side effects. These drugs have a therapeutic dose range 
that allows for the antipsychotic effect without inducing significant extrapyramidal side effects. 1 
  
In essence, the advantage of these drugs lies predominantly in their apparent reduced side effect 
profile, specifically fewer extrapyramidal side effects, rendering them more desirable and potentially 
improving compliance and thus contributing to relapse prevention. However it is important to be aware  
that SGA’s cannot be classified as a homogenous class and each drug has a individual side effect 
profile.2 Their efficacy is the same as for typical antipsychotics. The limiting factor with this class of 
drugs, especially in the state sector in South Africa, is the acqusition cost.3 They are more expensive 
and therefore are not extensively available due to budget constraints. 
   
Reports of treatment-emergent adverse events such as diabetes mellitus, diabetic ketoacidosis, 
hyperglycaemia and dyslipidaemia in patients receiving second generation antipsychotic agents have 
increased in recent times. This has led to growing concern about the link between metabolic 
complications and SGA use. 4 People with mental illness already have an increased risk of 
cardiovascular disease.5 This is due to a higher association of obesity, smoking, diabetes, hypertension 
and dyslipideaia.5 Lifestyle factors such as poor diet, sedentary lifestyle and stress also contribute to 
this higher risk.6 
  
It has been recognised that the incidence of metabolic syndrome in psychiatric patients is increasing.4 It 
is important for prescribing doctors to be aware and vigilant of this risk in order to prevent and manage 
it adequately.7 However, there is a lack of vigilance regarding monitoring and treatment of these 
patients among the medical community . It is felt that perhaps psychiatrists have a poor understanding 
of metabolic syndrome and are unsure about monitoring, diagnostic and treatment protocols.5 Another 
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factor that could contribute to this problem is that, in general, psychiatric clinics and hospitals are 
poorly equipped to handle any physical problems. For example limited choices of medication to treat 
general medical conditions.8 Psychiatric patients face numerous barriers with regard to access and 
quality of medical care.9  
 
Based on the awareness of metabolic consequences of prescribing SGAs, protocols, such as those 
arising from the Consensus Development Conference on Antipsychotic Drugs and Obesity and 
Diabetes, have been formulated for monitoring metabolic status.5 
 
Metabolic complications in patients prescribed olanzapine 
Olanzapine 
Olanzapine was the third second generation antipsychotic to be developed. It was introduced in 1996 
and since then has been a popular choice of antipsychotic. The link between diabetes, hyperglycaemia, 
lipid dysregulation and olanzapine has been extensively explored.4 
  
Olanzapine and weight 
Olanzapine has been shown to be responsible for both short term and long term weight gain. According 
to the manufacturer 29% of patients taking olanzapine for a period of 6 weeks will observe weight 
gain. A large meta-analysis reported weight gain at an average of 4 kg over 10 weeks in the short term, 
or in the long term as an average of 10kg over 28 weeks. Most weight gain occurs in the first year of 
commencing the drug and is due to an increase in fat mass/ body fat.4 The mechanism of weight gain is 
insulin resistance, and is not affected by the dose of the drug.10 
  
Olanzapine and Diabetes 
The FDA MedWatch Drug Surveillance System is one of the main systems responsible for studies and 
reports that show a significant link between olanzapine and diabetes or hyperglycaemia.4 There was a 
relationship between initiation of olanzapine therapy and the development of diabetes/hyperglycaemia. 
This relationship was reversible on discontinuation of olanzapine treatment. 80% of patients had 
improved glycaemic control after stopping treatment. About half of the newly diagnosed diabetes 
occurred within 3 months of starting treatment. 70% occurred within 6 months.4 The MedWatch study 
also reported a significant number of cases of diabetic ketoacidosis.11 34.6% of the cases of 
hyperglycaemia reported by the MedWatch study were associated with metabolic acidosis or 
ketoacidosis. Ketosis or acidosis was reported in 9 of the deaths in the MedWatch study.11 Therefore 
>10% of the cases of diabetic ketoacidosis were associated with patient death. An increase in plasma 
insulin levels is documented with olanzapine. This increase causes a reduction in insulin sensitivity. 
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This increased risk of diabetes is strongly related to increased adiposity which occurs as a result of the 
weight gain.4 
  
Olanzapine and Hyperlipidaemia 
There is consistent evidence that olanzapine has adverse effects on plasma lipids, specifically plasma 
triglycerides.4 This correlates with the effects of increasing abdominal fat mass on insulin sensitivity 
and lipid metabolism. An analysis of data from the UK General Practice Research Database shows a 
statistically significant increase in the risk of hyperlipidaemia with olanzapine as compared with 
patients on either typical antipsychotics or no antipsychotic treatment.12 
There was also a significant increase in triglycerides from pre-treatment levels with olanzapine. 
Elevated triglyceride levels are an independent risk factor for cardiovascular disease, as well as, 
appearing to contribute towards diabetes.13 
  
There is a statistically significant relationship between weight gain and elevated triglyceride levels. 
Increased cholesterol levels are also associated with weight gain and BMI in patients treated with 
olanzapine.4  
  
Given the aforementioned data, it is clear that olanzapine is associated with a range of side effects that 
may impact on physical health. Specifically, that olanzapine may place patients at risk for metabolic 
syndrome.4 
 
Metabolic syndrome 
Metabolic syndrome has assumed increasing significance. Whilst a number of definitions exist, there is 
some consensus on the following constellation of metabolic abnormalities that result in metabolic 
syndrome:- 14 
• centrally distributed obesity 
• decreased high-density lipoprotein cholesterol (HDL-C)  
• elevated blood pressure  
• hyperglycaemia 
These abnormalities are cause for concern as they all contribute to cardiovascular morbidity and 
mortality.5 Therefore, it is important to screen for these abnormalities so that effective treatment or 
preventative measures can be instituted, thus decreasing the risk of cardiovascular disease and thereby 
improving quality and quantity of life. In an attempt to achieve this, definitions have been formulated 
by various groups including the World Health Organisation (WHO); European group for the study of 
insulin resistance (EGIR); National Cholesterol Education Program of the USA and the International 
Diabetes Federation (IFD).15 
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 World Health Organisation (WHO) 
This was the first attempt at a global definition for metabolic syndrome. It was published in 1999 and 
comprised:- 14 
  
Diabetes or impaired glucose tolerance or insulin resistance. 
  
Plus 2 of the following 
  
• Obesity: BMI >30kg/m2 or  
 WHR>0.9 (male) or >0.85(female)  
• Dyslipidaemia  
 Triglycerides >= 150mg/dl (1.7mmol/l) 
 or HDL-C <35mg/dl (0.9mmol/l)-male <39mg/dl(1.0mmol/m)-female 
• Hypertension 
 BP >= 140/90 mmHg or on medication 
• Microalbuminuria 
 albumin excretion >= 20Ug/min or albumin:creatinine ratio >= 30mg/g 
  
The limitation of this definition is the need to use a of euglycaemic clamp to measure insulin 
sensitivity, thus making it difficult to use in clinical practice and epidemiological studies.14 
 
European group for the study of insulin resistance (EGIR)  
EGIR modified the WHO definition to use fasting glucose instead of microalbuminia. Whilst they felt 
that insulin resistance was the underlying cause of metabolic syndrome, they restricted the definition 
and only included those in whom insulin resistance could easily be measured.14  
  
Insulin resistance or hyperinsulineamia (only in non-diabetic subjects) 
  
Plus 2 or more of the following 
  
• Central obesity:  
• Waist circumference >= 94cm (male); >= 80cm (female) 
• Dyslipidaemia 
• Triglycerides > 177mg/dl (2.0mmol/l) or HDL-C < 39mg/dl (1.0mmol/l) 
• Hypertension: 
• BP >= 140/90 mmHg or on medication 
• Fasting blood glucose: 
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• >= 110mg/dl (6.1mmol/l) 
  
The problem with this definition (EGIR) is that people with diabetes were excluded from the definition. 
The reason being that beta-cell dysfunction in type 2 diabetes makes the estimates of insulin sensitivity 
unreliable.14 
  
National Cholesterol Education Program of the USA (Adult Treatment Panel III definition; ATP 
III) 
Two years later, in 2001, the National Cholesterol Education Program of the USA introduced the ATP 
III definition. This definition was designed to be more useful for clinical practice. It does not measure 
insulin resistance and treats all components with equal importance. This has been the most popular 
definition because all of the components are easily measured in both clinical and research settings.14 
The definition is:- 
  
Three or more of the following:- 
• Central obesity:  
• Waist circumferences>102cm(male); >88cm (female) 
• Hypertriglyceridaemia 
• Triglycerides >= 150mg/dl (1.7mmol/l) 
• Low HDL-C <40mg/dl (1.03mmol/l)-male, <50mg/dl (1.29mmol/l)-female 
• Hypertension 
• BP>=130/85mmHg or on medication 
• Fasting plasma glucose  
• >= 110mg/dl (6.1mmol/l) 
 
As opposed to the WHO and EGIR definitions there is no threshold of criteria required to qualify for a 
diagnosis.  
 
International Diabetes Federation (IDF) 
In 2005 the IFD developed an even more practical definition. They felt that a globally applicable 
solution was needed to identify people at high risk for cardiovascular disease and diabetes. A 
consensus group was formed including representatives from organisations who had contributed to 
previous definitions. Their approach emphasized central obesity as a critical component.14  The 
following criteria were proposed:-   
  
• Central obesity 
• waist circumference - ethnicity specific * 
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 plus any 2 of the following 
• Raised Triglycerides 
• >= 150mg/dl (1.7mmol/l) or specific treatment for lipid abnormalities 
• Reduced HDL-Cholesterol 
• < 40mg/dl (1.03mmol/l) in males 
• <50mg/dl (1.29mmol/l) in females 
• or specific treatment for this lipid abnormality 
• Raised blood pressure 
• systolic >= 130mmHg 
• diastolic >= 85mmHg  
• or treatment of previously diagnosed hypertension. 
• Raised fasting plasma glucose 
• fasting plasma glucose >=mg/dl (5.6mmol/l) or previously diagnosed 
type 2 diabetes 
• if above 5.6mmol/l or 100mg/dl, Oral Glucose Tolerance Test is 
strongly recommended but is not necessary to define presence of the 
syndrome. 
 
• Ethnic group Waist circumference 
• Europids male>=94cm; female>=80cm 
• South Asians male>=90cm; female>=80cm 
• Chinese male>=90cm; female>=80cm 
• Japanese male>=85cm; female>=90cm 
(Sub-Saharan Africans; South and Central Americans; Eastern Mediterranean and Middle East - use 
European data until more specific data is available.) 14 
   
The prevalence rates of metabolic syndrome vary using the different diagnostic criteria as follows :-15 
IDF: 22.3% 
ATP III: 22.6% 
WHO: 15.4% 
 
Whilst it can be expected that in the general population 22.3% of people will have metabolic 
syndrome,14 this will differ from population to population. For example, the prevalence rate in the US 
is estimated at 20-30%; 30-40% among urbanised Indians. 30% of Iranians, 20% of Greeks and 17% in 
Italians.5 
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Implications of Metabolic Syndrome 
Metabolic syndrome increases the risk of developing diabetes and cardiovascular disease which can 
result in myocardial infarction and stroke. Even the presence of one of the defined metabolic 
abnormalities, increases the risk of cardiovascular disease. The risk increases proportionately with 
increased number of metabolic abnormalities. In a recent study of patients with existing vascular 
disease, the presence of metabolic syndrome was associated with advanced vascular damage measured 
by: carotid intima media thickness, ankle-brachial pressure index and albuminuria. A higher number of 
abnormal metabolic components were also associated with an increase in the advanced vascular 
damage indicators.5  
 
Implications for people with mental illness  
The prevalence of obesity and diabetes in individuals with schizophrenia and affective disorders is 
about 1.5-2 times higher than the general population.5 Therefore one should consider it an independent 
risk factor for metabolic syndrome. People with mental illness already have an increased risk of 
cardiovascular disease. This is due to a higher prevalence of obesity, smoking, diabetes, hypertension 
and dyslipidaemia. Lifestyle factors also contributed to this higher risk.5 
  
Other factors that may predispose to metabolic syndrome in the mentally ill include16,17 : 
• poor diet 
• lack of exercise 
• smoking 
• substance abuse 
• stress 
• medication that causes weight gain 
• adherence to prescribed medication 
• financial hardship 
• symptoms resulting in poor self esteem and lack of motivation 
• limited availability and co-ordination of medical care 
  
Psychiatric disease itself can lead to changes in energy intake and expenditure. This is as a result of 
changes in sleeping and eating patterns as well as a change in day to day activities.18 Individuals with 
schizophrenia are more likely to have an unhealthy lifestyle than the general population. There is some 
evidence to suggest that patients with schizophrenia have more visceral adiposity than healthy 
individuals. However, this is not a universal observation. It is a well supported theory that visceral fat 
deposition is linked to insulin resistance. Another contributing factor is smoking. It is very common in 
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patients with schizophrenia and effectively increases insulin resistance.18 It is estimated that 75% of 
patients with schizophrenia are smokers.4 
 
It has become clear that psychiatric patients are at increased risk of developing metabolic syndrome. It  
is important that this risk is agknowledged and managed by medical professionals. Psychiatric patients 
face numerous barriers with regard to access and quality of medical care.9 They especially receive 
poorer care for chronic conditions such as heart disease and diabetes.19 This leads to an increased risk 
of premature death.19 The key issue of adressing mentally ill patient’s physical needs needs to be given 
priority.20 
 
Monitoring for Metabolic Syndrome 
Visceral adiposity has a direct association with dyslipidaemia and glucose intolerance. Therefore 
weight gain seems to be the root cause of the metabolic complications associated with the use of 
second generation antipsychotics. Knowing this, we can appreciate the importance of regular charting 
of weight as an important tool in the monitoring of patients on second generation antipsychotics. 
  
At the consensus development conference on antipsychotic drugs and obesity and diabetes, the panel 
recommended that both baseline and follow-up monitoring should be done at baseline and then 
reassessed at 4, 8 and 12 weeks after the commencement of the second generation antipsychotics. 
They considered the following parameters to be most important for screening. 
  
• Personal and family history of obesity, diabetes, dyslipidaemia, hypertension, or cardiovascular 
disease. 
• BMI, which requires weight and height. 
• Waist circumference 
• Blood pressure 
• Fasting plasma glucose 
• Fasting lipid profile 21 
  
If weight gain is > 5% of the patient’s initial weight at any point during the treatment; it is recommend 
that treatment be changed to another appropriate antipsychotic even if they have become apsychotic 
and are well on treatment.  Blood pressure, fasting glucose and fasting lipid profile should be 
reassessed at 12 weeks. At one year the personal history, waist circumference, blood pressure, fasting 
plasma glucose should be reassessed. The lipid profile should be done every 5 years.21 
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If any abnormalities are noted, the panel recommends that appropriate treatment, for metabolic 
syndrome is initiated. Psychiatrists must also not hesitate to refer patients to specialist physicians. 
The panel also emphasised the importance of good nutrition and physical activity to help combat 
any metabolic complications.21 
 
Implimentation of Guidelines 
 
Sernyak, noted that the main conclusion of the Consensus Development Conference, which led to the 
relevent guidelines, was that psychiatrists need to pay more attention to patients’ physical needs and 
monitor for the metabolic effects of second generation antipsychotics.22 A study to evaluate the 
implementation of the guidelines was undertaken. Before the guidelines were released 7.8% of patients 
had their lipids tested at baseline. After the guidelines were released only 8.5% had lipids tested at 
baseline.23 In the international setting, guideline publication appears not to have influenced clinical 
practice. Guidelines do have many benefits. They inform doctors of evidence based practices thereby 
striving to minimise inadequate practices as well as standardise practices.  They can be useful in 
enabling the professional to evaluate what they are doing.23  Clearly they do not always succeed. 
 
It has been proposed that in order to improve patient care clinicians should:-22 
 
• Encourage a culture of healthy lifestyle in patients with mental illness. This may include visits 
to a dietician, or even healthy eating groups run by dietician.  
 
• Implement exercise programs 
 
• Routinely monitor weight 
 
• Build awareness of guidelines among patients and professionals 
 
• Implement electronic record keeping with automated prompts regarding monitoring of key 
indicators of health. 
 
• Establish who is going to be responsible for the monitoring, as opposed to just co-ordinating 
patient care. 
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Association between olanzapine and demographics 
 
A study by Wang et al identified factors associated with being prescribed one of the newer generation 
antipsychotics like olanzapine to include being elderly, having more education and being white.24 
Socioeconomic status and access to prescription benefits did not significantly alter the findings of 
Wang et al regarding the lower likelihood of non-white patients and patients of lower education levels 
to be given newer generation antipsychotics.24  
This suggests that the demographic profile of patients influences the prescribing patterns of doctors. 
The question must therefore be asked if the demographic profile influences the adherence of doctors to 
monitoring guidelines for cardiovascular and metabolic side effects. 
 
In summary, olanzapine is a widely prescribed second generation antipsychotic that can lead to 
metabolic syndrome which has serious implications for the patient. Second generation antipsychotic 
drugs are not a homogeneous class, and differ from each other in many ways.2  The risk for metabolic 
syndrome is significantly higher with olanzapine than other second generation antipsychotics.4 It is 
neccessary for prescribing doctors to be aware of this risk in order to prevent it; and/or manage it 
appropriately.7 Guidelines such as those arising from the Consensus Development Conference on 
Antipsychotic Drugs and Obesity and Diabetes, have been formulated for monitoring metabolic 
status.21   The current study aimed to establish the extent to which metabolic and cardiovascular 
screening and monitoring has been undertaken on patients who have been prescribed olanzapine in a 
specific setting. The hypothesis was that screening was suboptimal (i.e. less than 100%). 
 
The study objectives were:- 
• To describe the demographic profile, clinical diagnosis and risk factors for metabolic 
complications in a sample of patients receiving olanzapine.  
• To establish the extent to which metabolic and cardiovascular screening and monitoring has 
been undertaken on patients prescribed olanzapine.  
• To determine to what extent the patients’s demographics, diagnosis and metabolic risk factors 
influence the treating doctor’s adherence to screening guidelines.    
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Methods 
 
Setting 
The study was a cross sectional, retrospective descriptive study involving review of case records. It 
was undertaken in the outpatient department of Tara: The H. Moross Centre, a specialist psychiatric 
hospital, located in the greater Johannesburg area and affiliated to the Division of Psychiatry in the 
Faculty of Health Sciences at the University of the Witwatersrand. A convenience sample of all 
patients who had been prescribed olanzapine during 2008 between January and March were selected. 
Olanzapine was chosen not only as it is one of the most widely prescribed second generation 
antipsychotic drugs in this setting, but also because it is associated with increased weight gain, insulin 
resistance, hyperglycaemia and diabetes mellitus. These risks are significantly higher for olanzapine 
than for any other second generation antipsychotic.4 It has been suggested that the metabolic 
consequences of olanzapine should be considered by clinicians before prescribing it.7 
 
Sample 
The initial acquisition of the sample commenced in the outpatient department. There were two groups 
of patients, those who commenced olanzapine as  outpatients (n=16), and those who commenced as 
inpatients (n=23). 
Once the latter group (those commenced on olanzapine as inpatients) had been identified, it was 
necessary to review their inpatient files. This was necessary in order to establish the exact date of 
starting olanzapine and also to document any screening that may have occured as an inpatient. The data 
was collected using the same data capture sheet for either group. It was decided to compare and 
separate these groups as to get a more accurate account of the screening process, that was free from 
confouding variables. 
  
Measures 
The data capturing sheet (Appendix A) was based on the metabolic and cardiovascular screening 
instrument developed by Pfizer for patients receiving second generation antipsychotics and is used to 
determine the extent to which metabolic status is being monitored (Appendix B). This screening and 
monitoring instrument was adapted from the American Diabetes Association Consensus Development 
Conference on Antipsychotic Drugs, Obesity and Diabetes. It is based on an existing protocol for 
monitoring metabolic status.21 Included in the data capture sheet was information about the patients 
demographic details (gender/age/educational level/socioeconomic status), diagnosis, risk factors for 
metabolic syndrome and any existing, contributing medical problems as well as which patient group 
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they belonged to (inpatient initiated or outpatient initiated) 
 
Procedure 
The screening variables of body mass index, waist circumference and finger prick glucose test (HGT), 
were not included in the results as there was no data for these variables. The screening variables; blood 
pressure; formal glucose; weight; cholesterol and lipids were grouped into time periods. i.e. up to 4 
months (initial), 4 months to 1 year (intermediate) and more than one year (long term). These time 
frames were chosen as they reflect the frequency at which screening should occur i.e. up to 4 months, 
screening is done monthly; from 4 months to 1 year screening is done 4 monthly; and after 1 year, 
screening is done annually. If the guideline was being accurately followed the percentage of screening 
would be 100%. After the 4 month time period (initial), the paucity of data made it unhelpful to 
continue to calculate the percentage screening for each variable. However the number of times any 
screening test was done in the specific time period (initial, intermediate, long term) was determined. 
Other descriptive variables such as family history of medical illness, date of diagnosis of medical 
illness were not included in the analysis as the data collection revealled no information for these 
variables. 
Analysis   
Descriptive statistics were used to describe the sample in terms of: age; gender; race; marital status; 
highest level of education; hospital classification; diagnosis; risk factors and patient group.  
Frequencies for these variables were calculated.  
 
The frequency of screening for each variable during the initial time period was noted as per the 
guideline and reflected as a percentage of screening for each variable at each time point. i.e. total 
number of patients screened/total number of patients. Inpatient and outpatient initiated treatment data 
was then compared for the initial time peroid only. The number of times a screening test was done in 
each specific time period (initial, intermediate, long term) was also determined. 
 
Using Statisica, a computerised statisical program the following variables (gender; race; marital 
status; highest level of education; hospital classification; diagnosis; gender and patient group) were 
analysed for normal distribution. Only diagnosis, gender and patient group were normally distributed. 
Screenings in each time period were studied in relation to the diagnosis, gender and patient  group 
(inpatient or outpatient initiated) using the Fisher exact test, to ascertian whether any of these 
descriptive variables influenced the treating doctor’s adherence to screening guidelines. 
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Ethics 
The  protocol for this study was approved by the Human Research Ethics Committee at the University 
of the Witwaterand (protocol number M 070446). No identifying information appeared on the data 
capture sheet. Each entry of data was coded with a number that was cross referenced to the patient’s 
hospital number. The researcher was the only one with access to this list. This ensured that data could 
be checked should the need have arisen. (Appendix C) 
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Results  
Demographic profile 
The sample comprised of 19 females and 20 males. (48.72% female and 51.28% male).  The mean age 
of females in the sample was 52.38 years (SD=16.20) and the mean age of males was 41.28 
(SD=17.05) years. The sample were predominantly single ( 61.54% n=24 ) with the majority being 
white (79.49% n=31 ); most had either tertiary (43% n=17 ) or secondary (53.85% n =21 ) level of 
education. Only 2.56% (n=1) had only primary level education. The majority of patients (84.62% 
n=33) in this sample were classified as H1 patients. H1 refers to patients with an individual income of 
less than R36 000 per annum or a household income of less than R50 000 per annum. It is also used as 
a default classification for those patients without any income. Patients classified as H2 have an 
indivdual income of less than R72 000 per annum or a household income of less than R100 000 per 
annum. H3 patients have an indivdual income greater than R72 000 per annum or a household income 
of greater than R100 000 per annum.  Patients classified as P,  are patients who are externally funded or 
are being treated by a private practioner in a public hospital. This catergory also includes certain 
foreign nationals. These classifications are stipulated by the National Depaertment of Health. (Table 1) 
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Table 1:  Demographic characteristics of patients in the sample (N = 39) 
Gender                                                                                            N                           % 
               Female                 19  48.72 
               Male                  20  51.28 
Race 
 Black       5  12.82 
 Coloured      2  5.13 
 Indian       1  2.56 
 White       31  79.49 
 
Marital status 
 Divorced      4  10.26 
 Married      8  20.51 
 Single       24  61.54 
 Widowed      3  7.69 
 
Highest level of education  
 Primary      1  2.56 
 Secondary      21  53.85 
 Tertiary      17  43.59 
 
Hospital classification 
 H1       33  84.62 
 H2       2  5.13 
 H3       1  2.56 
 P                      3  7.69 
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Diagnostic profile 
With regards to the diagnoses of patients in the sample, 17,95%  (n=7) were diagnosed with 
bipolar 1 disorder, 7,69% (n=3) with major depressive disorder with psychosis, 20,51% (n=8) 
schizoaffective disorder and 53,84% (n=21) with schizophrenia. (Table 2) 
 
 
Table 2: Diagnosis of patients in the sample  (N= 39) 
 
Risk factors 
In 35.9%; (n=14) of the sample, no risk factors were documented. 15.38% (n=6) were documented as 
having no risk factors. Specific risk factors were as follows; 10,26% (n=4) with hypertension, 5,13% 
(n=2) with diabetes, 2,56% (n=1) with hyperlipidaemia, 5,13% (n=2) with obesity, 20,51% (n=8) were 
smokers. 5.13% (n=2) had multiple risk factors documented. None of the sample had cardiovascular 
disease as a risk factor.  (Table 3). There was no information as to the date of diagnosis of  non-
psychiatric illness.  
 
Table 3: Risk factors of patients in the sample  (N=39) 
 
Diagnosis                                                                                         N             % 
 Bipolar 1 disorder     7 17.95 
 MDD with Psychosis     3 7.69 
 Schizoaffective      8 20.51 
              Schizophrenia      21 53.84 
Risk factors                                                                                    N              % 
               Hypertension      4 10.26 
               Diabetes      2 5.13 
               Hyperlipidaemia     1 2.56 
               CVS disease      0 0 
               Obesity      2 5.13 
               Smoking      8 20.51 
                Not documented     14 35.90 
                Nil       6 15.38 
                Multiple*      2 5.13 
* one patient with hypertension and hyperlipideamia 
   the other with hypertention, hyperlipideamia and smoking 
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Patient group 
The total number of patients in the sample was 39. Of this; 41% (n=16) were initiated on olazapine as 
outpatients and 59% (n=23) were initiated on olanzapine as inpatients. (Table 4) 
 
Table 4: Patient group in the sample  (N= 39) 
Patient group                                                                                 N             % 
 Inpatient initiated     23 58.97 
 Outpatient initiated     16 41.03 
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Screening 
The screening variables of body mass index, waist circumference and finger prick glucose test (HGT), 
were not included in the results as there was no data for these variables. This means that screening 
using these variables either was not undertaken or undertaken but not recorded. 
 
At baseline, all screening variables for outpatient initiated treatment were less than 20% of the 
expected i.e. 100%. Gluocose testing was most frequently done at 19%, followed by lipid studies at 
13% and weight, cholesterol and blood pressure at 6%. Formal glucose, lipid studies and cholesterol 
were not recorded again after 1 month. At 2 months only blood pressure (6%) and weight (6%) were 
recorded. Between 2 and 4 months the screening of weight increased to 25%, but that of blood pressure 
remained constant at 6%. (Figure 1) 
 
 
 
Figure 1: Frequency of screening – outpatient initiated treatment (n=16) 
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The range of screening for inpatient initiated treatment for the relevant screening variables differed to 
those for outpatient initiated treatment. In general there was a higher level of screening, although it 
declined over time. Blood pressure (100%), then weight (73.91%) were most frequently assessed at 
baseline followed by lipid studies (21,74%), glucose (13,04%) and cholestrol (8,7%) levels. For all 
varaibles measured, the trend was for screening to decline over time. At 2 months only 3 parameters, 
blood pressure (52,17%), weight (8,70%) and lipid studies (4,35%) were screened. At 3 months only 
blood pressure (21,74%) was screened. At 4 months there was an increase in screening of weight, 
glucose and cholesterol, all having a frequency of  4,35%. Blood pressure screening continued to 
decline to 17,39%. (Figure 2) 
 
Figure 2: Frequency of screening – inpatient initiated treatment (n=23) 
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Comparing inpatient versus outpatient initiated treatment for each variable (Figures  3-7) there were 
apparent differences in the extent of screening. In general, screening was greater for inpatient initiated 
treatment then outpatient initiated treatment. It must be noted that inpatients follow-up as outpatients 
after discharge, thus over time screening is underaken as an outpatient, but for the purposes of this 
study such screening was not noted separately.  
 
Specific parameters 
(i)Blood pressure 
Figure 3 shows a much greater frequency of screening for blood pressure among inpatient initiated 
treatment. At baseline 100% of patients were screened, however screening then decreased to 17.39% 
by 4 months. Outpatient initiaited screening of blood pressure remains constant at 6% 
 
Figure 3: Comparing inpatient versus outpatient initiated treatment screening of blood 
pressure 
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(ii) Weight 
In Figure 4 inpatient initiated screening of weight at baseline is 73.91%. It then shows a downward 
trend to 3 months where no screening is done. By 4 months screening improves again to 6 %. The 
frequency of outpatient initiated screening starts off at 6 % and gradually increases after 3 months to 
25% at 4 months. 
 
Figure 4: Comparing inpatient versus outpatient initiated treatment screening of 
weight 
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(iii) Glucose 
The frequency of glucose screening (Figure 5) is greater at baseline in outpatient initiated treatment, 
than inpatient initiated treatment (19% vs 13.4%). By 4 months inpatient initiated treatment shows 
slightly more screening, than outpatient initiated treatment (4.35% vs 0%).  
 
Figure 5: Comparing inpatient versus outpatient initiated treatment screening of 
glucose 
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(iv) Cholesterol 
In Figure 6 at baseline more patients initiated on treatment as inpatients were screened for cholesterol 
than patients initiated on treatment as outpatients ( 8.7% vs 6%). Screening then dropped to zero for 
both groups until the 4th month were inpatient initiated screening increased to 4.35%.  
 
Figure 6: Comparing inpatient versus outpatient initiated treatment screening of 
cholesterol 
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(v) Lipid studies 
Screening of lipid studies (Figure 7) was greater for inpatient initiated treamtment than outpatient 
initiated treatment (17.39% vs 13%). The frequency showed a downward trend to 4 months where it 
was zero for both groups. 
 
Figure 7: Comparing inpatient versus outpatient initiated treatment screening of lipid 
studies 
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Number of screenings in each time period 
Data as percentages was not reported for the intermediate and long term time periods due to very little 
screening being done. The total number of screenings in each time period (initial, intermediate, long 
term) were as follows: during the initial time period a total of 122 screening tests was done; in the 
intermediate and long term time periods 17 and 26 screening tests were done respectively. (Figure 8) 
 
Figure 8 : Number of screenings in each time period 
 
 
Variables associated with screening 
The variables of diagnosis, gender and patient group were normally distributed, and their association  
with screening in each time period (initial, intermediate, long term) was studied using the Fisher extact 
test. The Fisher exact test was used as a test for association because the variables were independent and 
categorical  (Table 5) 
 
Table 5: Variables associated with screening – p values 
 Initial time period Intermediate time 
period 
Long term time period 
Diagnosis p=0,68 p=0,13 p=0,13 
Gender p=1,0 p=0,13 p=0,48 
Patient group p=1,69x105 p=0,29 p=0,72 
 
No statistical significance (p-values > 0.05) was established. This confirms that there is no significant 
association between these variables and screening. This was most likely due to very little screening 
being undertaken or recorded. 
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Discussion 
 
The majority of patients in this sample were middle aged, white, single and diagnosed with 
schizophrenia. Most patients had completed secondary or tertiary education, but were in the lowest 
income group.  
Demographic profile 
Age and Gender 
The mean age of the sample was 46 years, which indicates that this sample comprises mostly middle 
aged patients who have possibly had a psychotic illness since their 20’s. This suggests that they are not 
a neuroleptic naive group, and have most likely been on other antipsychotic treatment before they were 
changed to olanzapine. The mean age of males was about 10 years younger than the mean age of 
females. Males usually have an earlier onset of psychotic illness than females25, however this does not 
necessarily account for the gender difference in age noted in this study. 
 
Race 
White patients comprised the majority of the sample. This demographic profile was not reflective of 
the South African population 
 
Marital status 
Premorbid personality of patients with schizophrenia is characterised by shy, schizoid behaviour.26  
These traits as well as communication and interpersonal deficits may account for the high proportion of 
unmarried patients with severe mental illness.27 Demographic data of patients with severe mental 
illness shows that a high percentage of these patients are unmarried.28,29 
 
Educational level 
The finding of a generally higher level of education within the context of olanzapine prescribing is in 
keeping with a study by Wang et al, where it was found that factors associated with being prescribed 
one of the second generation antipsychotics like olanzapine include being elderly, having more 
education and being white.24 One could speculate that better educated patients may report more side 
effects, than less educated patients. This is potentially why they have been prescribed olanzapine, 
which does have an improved extra pyramidal side effect profile. It is necessary for further studies to 
clarify the reason for this discrepancy in educational level in patients prescribed olanzapine. 
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Socio economic status 
Most patients in this sample were classified as falling into a lower socioeconomic group. H1 is the 
code used by the National Department of Health to describe the lowest level of income in patients 
registering for medical services. Patients are charged according to their income, therefore if they are 
registered as H1 patients they pay only a small nominal fee for services.  This is not  unexpected, as 
patients with severe psychotic illness display a phenomenon called ‘downward drift’.25 After multiple 
relapses and time spent unemployed, a patient’s financial position deteriorates, moreover Tara is a state 
hospital. Patients who can afford private care would perhaps be seeing private psychiatrists.  Of interest  
is that it appears that educational level does not predict socioeconomic status, in the sample studied, 
and that educational level in this setting is a better predictor of prescribing. 
 
Risk factors 
In 35.9%; (n=14) of the sample, no risk factors were documented with 15.38% (n=6) documented as 
having no risk factors. Specific risk factors were as follows; 10,26% (n=4) with hypertension, 5,13% 
(n=2) with diabetes, 2,56% (n=1) with hyperlipidaemia, 5,13% (n=2) with obesity, 20,51% (n=8) were 
smokers. 5.13% (n=2) had more than one or more risk factors documented. None of the sample had 
cardiovascular disease as a risk factor. Of concern, with regard to risk factors for metabolic syndrome, 
is that in more than a third of the sample the risk factors were not documented. It is not clear whether 
this was on the basis of there being no risk factors or simply that they were not elicited for whatever 
reason. 80% of schizophrenic patients have significant co-morbid medical problems, and in 50% of 
patients the problem may not have been diagnosed.25 This highlights the need for adequate history 
taking and accurate record keeping in relation to medical aspects of psychiatric patient care. The 
potential association between extent of risk factors documented and screening was not subject to 
formal statisical analysis. However, based on the documented existence of risk factors and the extent of 
screening, it does not appear that the former influenced the latter. 
 
Patient group 
More patients were initiated on olanzapine as inpatients (n=23) as opposed to as outpatients. This  is  
because inpatients are likely to be more severely ill than outpatients. During an admission it is more 
likely that medication will be reviewed and changed especially when treatment failure or adverse side 
effects negatively impact on recovery and remission of mental illness. 
Screening 
The percentage of screening for each of variables for outpatient initiated treatment was less than 20% 
and it continued to decline to less than 20% until 4 months. Beyond this there was so little screening as 
to render data interpretation of no value. The exception was weight, where frequency increased slightly 
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over time. The extent of screening for inpatient initiated treatment, for the relevant screening variables, 
differed to those for outpatient initiated treatment. In general there was a higher level of screening, 
although it declined over time. Weight and blood pressure were most frequently assessed at baseline 
followed by lipogram, glucose and cholestrol levels. For all variables measured, the trend was for 
screening to decline over time. Comparing inpatient versus outpatient initiated treatment there were 
apparent differences in the extent of screening i.e. greater for inpatient initiated treatment, specifically 
with respect to weight and blood pressure. It was clearly noted that inpatient screening is superior to 
screening undertaken as an outpatient. However weight and BP monitoring are a part of  standard 
nursing procedure in the wards at Tara: The H. Moross Centre and is therefore undertaken on all 
patients and is not specific to patients on olanzapine. Hence one should be cautious in over interpreting 
the apparent screening. In summary, screening for metabolic syndrome in patients on olanzapine is not 
being undertaken according to recommened clinical guidelines. 
 
Number of screenings in each time period 
Screening was most frequently undertaken during the initial period, with a marked reduction during the 
subsequent periods. The study did not allow for exploration of the basis, nonetheless the finding is 
noteworthy and requires elucidation.  
 
Factors associated with screening 
No significant relationship was established regarding the extent to which the patient gender, diagnosis 
or patient group influenced the treating doctor’s adherence to screening guidelines. The limited sample 
size and paucity of data, suggests that this finding should be cautiously interpreted.  
 
Adherence to guidelines 
The findings of this study revealed that screening for metabolic syndrome in patients on a second 
generation antipsychotic is not being conducted according to recommended clinical practice, in the site 
studied. In essence, guidelines are being overlooked or ignored for whatever reason. Perhaps one of the 
main limitations of any guideline is its implementation. It is therefore worth exploring some of the 
pitfalls in implementation. Firstly, it may be that treatment options are not available.22 It may be that 
we lack some of the basic tools needed to follow the guidelines accurately. For example, in order to 
measure waist circumference one needs a tape measure, which is not a piece of equipment commonly 
found in a psychiatric outpatient department. The guidelines may be too extensive, and not user 
friendly.22 The guideline that was analysed in this study required 8 measurements to be taken at 
numerous time periods.16 This is time consuming for both the patient and the doctor, and one may 
question whether these measurements are indeed necessary. In the pathogenesis of metabolic 
syndrome, one of the first steps is weight gain, which results in the subsequent insulin resistance and 
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dyslipideamia. One could argue that monitoring weight is an adequate screening tool for metabolic 
syndrome and once weight gain is noted then all the other tests/measurements can be performed. Hence 
it may be that local circumstances prompt reappraisal and modifcation of guidelines rendering them 
user friendly without compromising outcomes. Another limitation to guidelines is the credibility of the 
authors.30 The authors of the guidelines appear reputable and the guidelines were formulated at an 
international consensus conference. Possibly the most likely causes of non compliance to guidelines are 
a lack of awareness of the guideline and/or a resistance to change. These guidelines were published in 
2004, but only in recent years has more attention been drawn to them. Perhaps one of the factors in our 
setting was the lack of familiarity with the guidelines, hence the non-adherence. 
 
As mentioned previously; a study to evaluate the implementation of the guidelines was undertaken.23 
Before the guidelines were released 7.8% of patients had their lipids tested at baseline. After the 
guidelines were released only 8.5% had lipids tested at baseline.23 This is comparable to the current 
study where at baseline 6-8.7% of patients had their lipids tested. 
 
Hence one sees that baseline rates of testing locally are comparable to international data. However, one 
sees that in the international setting, guideline publication appears not to have influenced clinical 
practice. Guidelines do have many benefits. They inform doctors of evidence based practices thereby 
striving to minimise inadequate practices as well as standardise practices.  They can be useful in 
enabling the professional to evaluate what they are doing.23  Clearly they do not always succeed. 
 
Based on the findings of the current study it appears there is a need to actively encourage the benefits 
of guidelines locally. 
 
Limitations 
This study consisted of a cohort of 39 patients from Tara: The H. Moross Centre. Not only is this a 
small sample size, but the data cannot be generalized beyond this setting i.e. a tertiary, specialised 
hospital. As in all retrospective studies poor record keeping is a limitation. In the current study this 
appears to have been an issue. Again this highlights the importance of good record keeping by medical 
professionals. This study is also a cross sectional anaylsis and refers to information gathered at a 
particular point in time only i.e. patients who were prescribed olanzapine in 2008. 
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Conclusion 
There is strong evidence that people with mental illness have less access to primary health care. They 
also receive poorer care for conditions such as diabetes and heart disease.19 The rates of physical illness 
are high in mentally ill patients, especially the rates of cardio-vascular disease, obesity, diabetes and 
Human immuno-deficiency virus (HIV). The combination of high rates of physical illness and poorer 
quality of treatment exacerbates both discrimination and neglect. Thus patients with mental illness have 
an increased risk of premature death.19 The suggestion is that psychiatric patient’s physical health is 
being overlooked. Thus, the issue of physical health in persons with severe mental illness has assumed 
both public health and ethical relevance on a global scale.20 This key issue needs to be made a priority 
in order to protect the civil rights of our patients.20  
 
The hypothesis of the study has been confirmed i.e. screening was suboptimal. Refining clinical 
practice will hopefully contribute to a greater awareness, both specifically and generally of the physical 
needs of psychiatric patients and ultimately their care. The current study has in a very specific setting, 
demonstrated an area requiring attention i.e. adherence to acceptable clinical practice. Whilst one can 
only speculate on the basis for non-adherence, having established the status quo, there is a requirement 
for an appropriate strategy to address this apparent deficit in patient care. Awareness of clinical 
guidelines addressing the physical needs of patients needs to be highlighted to doctors and patients. In 
addition healthly lifestyle should not be overlooked as an effective intervention. Perhaps further studies 
should aim to collect similar data in other settings, in order to establish the extent of the problem on a 
regional or even national scale. It may also by useful to research and identify the key reasons for non-
adherence to guidelines. This may ultimately result in an adapted protocol being designed, specifically 
for the South African setting.  
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Data collection sheet : 
 
Number: 
 
Demographics 
 
Age:  
 
Gender:   male  □  female  □ 
 
Race:      White  □   Black □   Coloured □   Indian □ 
 
Marital status:   single  □ married □ divorced □ widowed □ 
 
Highest level of education:  actual level:          primary □   secondary □    tertiary  □ 
 
Hospital classification :    H1 □   H2□   H3□   P 
 
Diagnosis 
 
1.Schizophrenia   2. Bipolar Mood Disorder  3. Other (specify) 
 
 
Date of starting Olanzapine:   dd/mm/yy  
 
Patient group 
 initiated as inpatient  
 initiated as outpatient  
 
Risk factors  
 
1. Hypertension 2. Diabetes  3. Hyperlipideamia  4.Cardiovascular disease  
 
5.Obesity   6. Smoking   7. Not documented 8. Nil  
 
Monitoring 
 
                         BP     HGT    formal glucose     weight     BMI     waist circumference     cholesterol     fasting lipogram            
 
Baseline 
 
1 month 
 
2 months 
 
3 months 
 
4 months 
 
> 4 months 
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 1 year 
 
yearly 
 
every 5 years 
 
 
            
            
            
           
            
           
Diagnosis of any non-psychiatric il lness by any medical professional post intervention 
with second generation antipsychotics. 
 
1. Hypertension  2. Diabetes  3. Hyperlipidaemia  4. Cardiovascular disease 
 
Date of diagnosis of non-psychiatric illness:   dd/mm/yy 
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